UPDATE: Deutsche Bank Raises PT on Vertex Pharmaceuticals on 661 Data
April 19, 2013 at 11:21 AM EDT
In a report published Friday, Deutsche Bank analyst Robyn Karnauskas reiterated a Buy rating on Vertex Pharmaceuticals (NASDAQ: VRTX ), and raised the price target from $75.00 to $100.00. In the report, Karnauskas noted, “661 data released today beat our positive expectations. We now model c100% success in F508del homozygous
